How to overcome antiviral-resistant hepatitis B virus?

Related Experiment Video

Updated: Jun 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Byung-Cheol Song1

  • 1Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. drsong@jejunu.ac.kr

Intervirology
|January 14, 2010
PubMed

Insights

Preventing antiviral resistance is key to successful chronic hepatitis B treatment. This review discusses strategies to maintain long-lasting suppression of hepatitis B virus (HBV) DNA and prevent treatment failure.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) treatment aims for sustained hepatitis B virus (HBV) DNA suppression and prevention of liver disease progression.
  • Oral nucleoside/nucleotide analogs have advanced CHB therapy over the last decade.
  • Antiviral resistance remains a primary cause of treatment failure in CHB.

Purpose of the Study:

  • To review and discuss strategies for preventing antiviral resistance in chronic hepatitis B patients.
  • To highlight the importance of resistance prevention for long-term treatment success.
  • To provide insights into managing HBV DNA suppression and preventing disease progression.

Main Methods:

  • Literature review of studies on antiviral resistance in chronic hepatitis B.
  • Analysis of treatment outcomes with nucleoside/nucleotide analogs.
  • Discussion of clinical management approaches to prevent resistance.

Main Results:

  • Emergence of antiviral resistance is a significant challenge in CHB management.
  • Effective prevention strategies are crucial for sustained viral suppression.
  • Understanding resistance mechanisms informs therapeutic decisions.

Conclusions:

  • Preventing antiviral resistance is paramount for achieving long-term goals in CHB therapy.
  • Proactive management strategies are necessary to overcome treatment failures.
  • Continued research is needed to optimize antiviral therapies for CHB.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...